Gene-Edited immune cells take on lupus and scleroderma in first human test
NCT ID NCT06925542
First seen Oct 31, 2025 · Last updated Apr 30, 2026 · Updated 18 times
Summary
This early-stage study is testing a one-time treatment called CTX112, made from donor immune cells edited with CRISPR technology. It aims to see if it is safe and can help adults with severe lupus, scleroderma, or myositis that haven't improved with standard treatments. About 80 participants will receive the therapy and be monitored for side effects and signs of disease improvement.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SYSTEMIC SCLEROSIS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Research Site 1
RECRUITINGSt Louis, Missouri, 63130, United States
-
Research Site 2
RECRUITINGChicago, Illinois, 63110, United States
-
Research Site 3
RECRUITINGHanover, 30625, Germany
-
Research Site 4
RECRUITINGRedwood City, California, 94063, United States
-
Research Site 5
RECRUITINGChapel Hill, North Carolina, 27599, United States
-
Research Site 6
RECRUITINGBoston, Massachusetts, 02118, United States
-
Research Site 7
NOT_YET_RECRUITINGAugsburg, 86156, Germany
-
Research Site 8
RECRUITINGIowa City, Iowa, 52242, United States
Conditions
Explore the condition pages connected to this study.